Gang Qin

CEO, Founder & Chairman at GeneQuantum Healthcare

Speaker

Dr. Gang Qin has more than 16 years of R&D and managing experiences in biomedical research. He obtained his PhD degree in 2005 at the European Neuroscience Institute Goettingen, Germany. Then he joined Max-Planck Institute of Biochemistry at Munich focusing on mechanistic characterization of protein degradation regulated cell proliferation. Thereafter, he moved back China and led one team at National Laboratory for Industrial Enzyme Engineering, CAS, there Dr. Qin dedicated himself to the field of enzyme engineering and chemical biology.

In 2013 Dr. Qin founded GeneQuantum Healthcare (Suzhou ) Co. Ltd, currently he is the president. Dr. Qin has published series of high citation paper in international peer reviewed Journals including Journal of Neuroscience Nature Neuroscience、Neuron etc., he is also major inventor of multiple PCT patents. GeneQuantum’s innovative Ligase Dependent Conjugation (LDC) technology, combined with IP protected Automatic On-line Monitoring Conjugation System and Linker Screening& Optimization Facility, provide a holistic solution for the R&D of next generation ADCs. GeneQuantum are focusing on developing series of next generation anti-tumor Antibody-Drug-Conjugates (ADCs) with best-in-class or first-in-class potential fulfilling the unmet clinical need.